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Due to the great progress and development of modern technology, our understanding 
of neuropsychiatric disorders biological, physiological, and metabolic processes has 
advanced tremendously. However, we still face many challenges in drug discovery 
and development targeting because neuropsychiatric disorders have a complex 
etiology with multiple points of possible intervention. This is also apparent in 
consideration of the plurality of targets that bind antipsychotics, anti-Parkinsonian, or 
antidepressant drugs, indicating the need to develop multi-target compounds for a 
polypharmacological approach  (Hopkins, 2008).  
 
Understanding the interactions of neurotransmission systems especially among 
monoamines is an important step for the optimization of therapeutic strategies for 
many if not all of these neuropsychiatric disorders. Neurotransmitters such as 
dopamine, serotonin, noradrenaline or histamine play a central role in the 
pathophysiology of major neuropsychiatric illnesses, including anxiety and mood 
disorders, schizophrenia, autism-spectrum disorders, Parkinson’s disease, epilepsy, 
and dementias (De Deurwaerdère & Di Giovanni, 2016; Simic et al., 2016; Venzi et 
al., 2016). Numerous medicines targeting monoaminergic systems have been used 
successfully but most require adjustments due to the emergence of side effects. 
However, the efficacy of these medicines stress that the strategy to correct abnormal 
signalling of monoaminergic neurotransmitters is appropriate. A further complication 
arises in that monoaminergic systems establish close relationships with other 
neurotransmitter systems (Chesselet, 1984), so it is likely that a pharmacological 
action toward one system will more or less directly affect the other one. This is 
highlighted by well-known associations such as the 5-HT/DA interaction (De 
Deurwaerdère & Di Giovanni, 2016; Di Giovanni et al., 2008; Di Matteo et al., 2008), 
the glutamate/DA interaction (Carlsson & Carlsson, 1990), and the 5-HT/GABA 
interaction (Crunelli & Di Giovanni, 2014; Soubrie, 1986). Moreover, 
neurotransmitter-binding proteins such as receptors, transporters and common 
metabolic enzymes have commonalities in their binding sites that must be considered 
as the starting points for development of new tools to diagnose and drugs to treat 
specific clusters of symptoms.  
 
The European Cooperation in Science and Technology (COST, Figure 1) Action 
CM1103 “Structure-based drug design for diagnosis and treatment of neurological 
diseases: dissecting and modulating complex function in the monoaminergic systems 
of the brain” is a good example of the advances possible through interdisciplinary 
collaboration on these difficult problems (see 
http://www.cost.eu/COST_Actions/cmst/CM1103). During the four year life of the 
Action, different European laboratories using innovative computational approaches 
contributed to the analysis of the pharmocophores, identified novel hits, and verified 
the suitability of new compounds against multiple targets. New series of compounds 
were synthesized and assessed experimentally against the design targets for 
Alzheimer’s disease (AD) such as monoamine oxidases (MAO) and cholinesterases 
(ChE), then promising leads examined for other beneficial properties such as anti-
oxidant activity and promoting cell survival. Compounds addressing new 
combinations of targets have also been developed. At the organism level, compounds 
have also been examined in animal models of epilepsy and vascular dementia, and 
linked to human data by members involved in translational research (see (De 
Deurwaerdere et al., 2016; Ramsay & De Deurwaerdere, 2014; Ramsay & Di 
Giovanni, 2014). The articles contributed here present some of insights gained during 
the collaborative research and other contributions from researchers working in this 
field.  
 
 
Figure 1.  European Cooperation in Science and Technology. COST is a pan-European 
intergovernmental framework. Its mission is to enable break-through scientific and technological 
developments leading to new concepts and products and thereby contribute to strengthening Europe’s 
research and innovation capacities. It allows researchers, engineers and scholars to jointly develop their 
own ideas and take new initiatives across all fields of science and technology, while promoting multi- 
and interdisciplinary approaches. 
 
 
The purpose of this special issue is to collect relevant research and review papers 
covering the wide spectrum of the neuropathology and neuropharmacology of 
monoaminergic systems. Guiard and colleagues (Zemdegs et al., 2016) report on the 
bidirectional link between type 2 diabetes mellitus (T2DM) and depression. These 
metabolic and mental disorders are major public concerns since each pathology 
affects 350 millions people worldwide and have terrific economic impact. Although 
growing evidence support that T2DM may cause depression, some important issues 
have yet to be clarified. In particular, the neurobiological mechanisms by which 
T2DM negatively reverberates on mood and to what extent it might influence the 
therapeutic outcome of serotonergic antidepressant drugs are two crucial questions 
that were addressed in this study. In agreement with epidemiological data, the authors 
demonstrated that increased body weight, hyperglycaemia and impaired glucose 
tolerance were correlated with anxiogenic-/depressive-like symptoms in mice fed with 
a high-fat diet., They also emphasize (for the first time in this animal model of 
comorbid T2DM/depression) that such behavioural abnormalities were associated 
with decreased extracellular 5-HT levels in the hippocampus resulting from increased 
sensitivity of the dorsal raphe 5-HT1A autoreceptor. Moreover, the beneficial effect of 
prolonged administration of escitalopram was abolished in mice fed a high fat diet. 
On the contrary, withdrawal of the high fat diet completely reversed the metabolic 
impairments and positively changed symptoms of anxiety, although some behavioural 
anomalies persisted. In a context of increasing prescription of antidepressant 
medication (Mojtabai & Olfson, 2014), understanding and predicting response to 
specific treatment could have benefits not only as regards the economic burden 
related to depression but also for the patients. This study shed some light on the fact 
that stabilizing metabolic parameter would be a prerequisite before expecting 
beneficial effects of antidepressant drugs, notably SSRIs, in the comorbidity of T2DM 
and depression. This hypothesis paves the way for clinical investigations that might 
help identifying the most adequate therapeutic strategy. 
Two contributions from Bortolato and colleagues (Godar et al., 2015) are studies 
focused on dopamine and its receptors in the regulation of prepulse inhibition (PPI) of 
the acoustic startle, a well-known cross-species index of sensorimotor gating, 
typically impaired in several neuropsychiatric disorders featuring dopaminergic 
imbalances, such as Tourette syndrome (TS), schizophrenia and mania. D1CT-7 mice, 
one of the best-characterized animal models of TS, exhibit PPI deficits in response to 
short-term spatial confinement (SC). These D1CT-7 mice are characterized by a 
neuropotentiating transgene in select populations of neurons containing D1 dopamine 
receptors, and exhibit specific tic-like responses. A mild environmental stressor also 
produced a significant exacerbation in tic-like responses, in a fashion sensitive to 
benchmark therapies for TS. Taken together, their data highlight a novel experimental 
platform to study the neurobiological links between environmental stress and TS 
manifestations (including tic-like responses) in animal models. The second study 
(Mosher et al., 2015) showed that hooded Long-Evans rats display PPI deficits in 
response to the selective activation of both D1 and D2 dopamine receptors. 
Conversely, only D2 agonists have PPI-disrupting properties in Sprague-Dawley and 
Wistar albino rats. One of the first-documented examples of D1 sensitivity in PPI in 
rats, this model may prove valuable to study the involvement of the D1 receptor in rat 
models of TS, schizophrenia and mania. 
Moving more to studies where the interactions of the neurotransmission systems are 
relevant to degeneration, De Deurwaerdère and Ugedo (Miguelez et al., 2016) 
focused on the effect of the L-DOPA, the gold standard medication of Parkinson’s 
disease, on serotonergic system. L-DOPA therapeutic superiority compared to other 
medication is impaired by numerous side-effects including dyskinesia. Agonists at 5-
HT1A receptors can reduce L-DOPA-induced dyskinesia but these compounds have 
their own side-effects (Carta et al., 2007). Indirectly, the selective serotonin reuptake 
inhibitors could stimulate 5-HT1A receptors but their efficacy could be lowered due to 
the own effects of L-DOPA on serotonergic neuron activity (Navailles et al., 2011). 
Here, Miguelez et al. (2016) studied the acute and long-term L-DOPA effects and the 
activity of dorsal raphe serotonergic neurons in 6-OHDA-lesioned rats, a preclinical 
model of Parkinson’s disease. They found that the 5-HT1A receptor-dependent control 
of serotonergic neurons is unaltered in dyskinetic rats and that the SSRI fluoxetine 
loses its efficacy to inhibit the 5-HT1A receptor-dependent inhibitory control of 
serotonergic neurons in the presence of L-DOPA. This study raises caution to the use 
of SSRI in the treatment of depression or dyskinesia in L-DOPA-treated Parkinsonian 
patients (Miguelez et al., 2016) 
Also relevant to dyskinesia in Parkinson’s disease, is a review (García et al., 2016) of 
the evidence on cannabinoid–dopamine interactions emphasising the function of the 
basal ganglia and the control of movement. Dopaminergic neurons do not contain 
CB1 receptors but these receptors are located on neurons present in regions 
innervated by dopaminergic neurons, which allows relevant bidirectional interactions. 
However, additional direct mechanisms may also facilitate these interactions, for 
example, through TRPV1 and CB2 receptors located in dopaminergic neurons as well 
as through postsynaptic interactions of CB1 receptors with D1/D2 receptors. It is 
possible that cannabinoids might have therapeutic potential through these actions that 
can facilitate a normalization of dopaminergic transmission in states such as 
Parkinson’s disease. 
 
Ponimaskin and Kondaurova and their colleagues (Kulikova et al., 2016) propose an 
original work focusing on 5-HT1A receptors. The role played by presynaptic and 
postsynaptic 5-HT1A receptors in the action of antidyskinetic, antipsychotic, 
antidepressant or anxiolytic drugs is one of the main lines of research regarding 
serotonin-based medicines (De Deurwaerdère and Di Giovanni, 2016). Genetic 
predisposition regarding pre- and postsynaptic 5-HT1A receptor responses could 
condition distinct pharmacological responses and appropriate preclinical models are 
needed. The authors (Kulikova et al., 2016) created two mouse lines, B6-M76C and 
B6-M76B, by transfer of a chromosomic locus selected from CBA mice to C57BL/6 
genetic background. This locus, which predisposes CBA mice to catalepsy, contains 
5-HT1A receptor gene. They analysed the pharmacological, biochemical, cellular and 
behavioural properties in the two lines. The genetic transfer to the C57Bl6 led to 
decreased pre-synaptic and increased post-synaptic functional responses of the 5-
HT1A receptor. This feature makes the Bl6-M76C mouse an attractive model for the 
pharmacological screening of 5-HT1A receptor-related drugs specifically acting either 
on the pre- or post-synaptic receptors. 
 
The final article looks beyond the neurotransmitter systems to other factors affecting 
neuronal survival in the face of ageing and neurodegenerative diseases. Youdim and 
colleagues (Weinreb et al., 2015) reviewed the neuroprotective effects of hybrid 
agents targeting MAOs, cholinesterases, iron load, and β-amyloid accumulation in 
ageing and AD. Nowadays, AD is accepted as a complex neurodegenerative disorder 
with multifaceted cerebral pathologies and it is widely accepted that an effective 
therapy for AD could result from the use of multifunctional drugs affecting more than 
one target involved in the disease pathology. The potential benefits of novel 
multimodal neuroprotective, brain-permeable drugs, recently developed by Youdim 
and collaborators, are a valuable therapeutic approach for AD treatment.  
 
The key message from these studies is the cross-talk between systems. Fundamental 
research to identify key proteins that influence the functional pathways is essential for 
future multi-target drug design. In turn, multi-target compounds will aid the dissection 
of the complex pathways in neuropharmacology and our understanding of how the 
brain works and how best to normalise its function. 
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